2019-002849-38: A clinical study to assess the safety, systemic exposure and efficacy of a liquid for inhalation of budesonide (AQ001S) to treat asthma. étude de la sécurité, de l’exposition systémique et de l’efficacité d’un liquide pour inhalation de budésonide dans le traitement de l’asthme |
|
|
| Not yet recruiting | 2/3 | 24 | Europe | Budesonide inhalation solution 0.125 mg/ml, Nebbud 0.25 mg/2 ml, AQ001S 0.125 mg/ml, Inhalation solution, Nebbud 0.25 mg/2 ml zawiesina do nebulizacji | Aquilon Pharmaceuticals, Walloon Region (SPW-EER) | asthma, asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
BOREAS, NCT04933383: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics |
|
|
| Completed | 1/2 | 23 | Europe | AQ001S 0.125 mg/ml, budesonide inhalation solution 0.125 mg/ml, Budesonide 0.125 mg/ml inhalation suspension, Budesonide inhalation suspension 0.125 mg/ml | Aquilon Pharmaceuticals S.A. | Asthma | 12/22 | 01/23 | | |